Τόμος 32 (2018) – Τεύχος 3 –Άρθρο 5 – Review of Clinical Pharmacology and Pharmacokinetics – Διεθνής Έκδοση – Volume 32 (2018) – Issue 3 – Article 5 – Review of Clinical Pharmacology and Pharmacokinetics – International Edition

By | | Πλήρες Κείμενο στα Αγγλικά - Full Text in English
Τίτλος – Title
Is the glucose a risk factor for the Polycyclic ovary syndrome in Greek women? A retrospective study
Συγγραφέας – Author

Giannoula Kyrkou1, Eftichios Trakakis2, Achilleas Attilakos1, Kleanthi Gourounti3, Aikaterini Lykeridou3

1Third Department of Pediatric, University of Athens “Attikon” Hospital, Athens, Greece

2Third Department of Obstetrics & Gynecological, University of Athens “Attikon” Hospital, Athens, Greece

3Midwifery Department, University of West Attica, Athens, Greece
Παραπομπή – Citation

G. Kyrkou, E. Trakakis, A. Attilakos, K. Gourounti, A. Lykeridou.Is the glucose a risk factor for the Polycyclic ovary syndrome in Greek women? A retrospective study .Review Clin. Pharmacol. Pharmacokinet. 2018, 32, 3, 141-145
Ημερομηνία Δημοσιευσης – Publication Date
23-10-2018
Γλώσσα Πλήρους Κειμένου –
Full Text Language

Αγγλικά – English
Λέξεις κλειδιά – Keywords
Neuroendocrine Tumors, differentiation, classification, carcinoid syndrome
Λοιποί Όροι – Other Terms

Μελέτη Ανασκόπησης

Retrospective study
Περίληψη –Summary

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among reproductive age women. It is well documented that the prevalence of impaired glucose tolerance and diabetes is increased in women with PCOS.

Aim: Aim of this study was to investigate the prevalence of glucose in Greek women with PCOS.

Method and material: 230 Greek women, who have been diagnosed with PCOS according to the criteria of the Rotterdam ESHRE, aged from 12 to 44 years, have been included in the study. The fasting plasma glucose has been analyzed.

Results: 230 women participated in our study. 209 blood results were valid. The mean of fasting plasma glucose was 82 mg/dl, the mean median was 83 mg/dl and the standard deviation was 12,87 mg/dl. The means of blood fasting glucose was gradually elevated according to age group.

In conclusion: The prevalence of fasting plasma glucose was 7.4% in patients with PCOS. The pathogenesis of metabolic syndrome and its components are complex.

The glucose is perhaps considered to be pathogenetic factor in the development of PCOS. The adult women presented higher prevalence of fasting plasma glucose in comparison with adolescent girls, so it is necessary these women to have a systematic follow up.
Αναφορές – References
  1. Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril 2016;106:6–15.
  2. Tehrani FR, Simbar M, Tohidi M, Hosseinpanah F, Azizi F. The prevalence of polycystic ovary syndrome in a community sample of Iranian population: Iranian PCOS prevalence study. Reprod Biol Endocrinol 2011;9:39.
  3. Vrbikova J, Cifkova R, Jirkovska A, Lanska V, Platilova H, Zamrazil V, et al. Cardiovascular risk factors in young Czech females with polycystic ovary syndrome. Hum Reprod 2003;18:980–4.
  4. Yildiz BO, Bozdag G, Yapici Z, Esinler I, Yarali H. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod 2012;27:3067–73.
  5. Duleba AJ, Dokras A. Is PCOS an inflammatory process? Fertil Steril. 2012; 97: 7–12.
  6. Carmina E, Chu MC, Longo RA, Rini GB, Lobo RA. Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab. 2005; 90: 2545–2549.
  7. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2010;16:347–63.
  8. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141–6.
  9. Norman RJ, Masters L, Milner CR, Wang JX, Davies MJ. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or noninsulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod 2001;16:1995–8.
  10. Legro RS, Gnatuk CL, Kunselman AR, Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab 2005;90: 3236–42.
  11. Morgan CL, Jenkins-Jones S, Currie CJ, Rees DA. Evaluation of adverse outcome in young women with polycystic ovary syndromeversus matched, reference controls: a retrospective, observational study. J Clin Endocrinol Metab 2012;97:3251–60.
  12. The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19 No 1:41-47
  13. The IDF consensus worldwide definition of the metabolic syndrome. http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf, last accessed in August 2007
  14. The IDF consensus worldwide definition of the metabolic syndrome in children and adolescents

http://www.idf.org/webdata/docs/Mets_definition_children.pdf accessed in 2007

  1. Ferriman D, Gallwey JD (1961) Clinical assessment of body hairgrowth in women. J Clin Endocrinol Metab 21:1440–1447
  2. Kauffman, R.P., Baker, T.E., Baker, V.M., DiMarino, P., Castracane, V.D., 2008. Endocrine and metabolic differences among phenotypic expressions of polycystic ovary syndrome according to the 2003 Rotterdam consensus criteria. American Journal of Obstetrics and Gynecology. 198, 670.e1–670.e10
  3. Cheung LP, Ma RC, Lam PM, et al. (2008) Cardiovascular risks and metabolic syndrome in Hong Kong Chinese women with polycystic ovary syndrome. Hum Reprod 23:1431-143
  4. Carmina E, Napoli N, Longo RA, Rini GB, Lobo RA (2006) Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS Eur J Endocrinol 154:141-145
  5. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in with polycystic ovary syndrome. CLin Endocrinol Metab 2005; 90:1929-1935
  6. Carmina E, Legro RS, Stamets K, Lowell J, Lobo RA (2003) Difference in body weight between American and Italian women with polycystic ovary syndrome: influence of the diet. Hum Reprod 18:2289-2293
  7. Bhattacharya SM (2008) Metabolic syndrome in females with polycystic ovary syndrome and International Diabetes Federation criteria. J Obstet Gynaecol Res 34:62-66
  8. Dargham S, Ahmed L, Kilpatrick E, Atkin St. (2017) The prevalence and metabolic characteristics of polycystic ovary syndrome in the Qatari population.
Σχετικές Εργασίες – Relative Papers

Online ISSN 1011-6583

Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
• Chemical Abstracts

• Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE
SCImago Journal and Country Rank Factor

Articles published in this Journal are Indexed or Abstracted in:
• Chemical Abstracts
• Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE
SCImago Journal and Country Rank Factor

Τι είναι η Review of Clinical Pharmacology and Pharmacokinetics-Διεθνής Έκδοση-Οδηγίες προς τους Συγγραφείς
What is Review of Clinical Pharmacology and Pharmacokinetics-International Edition-Instrunctions to Authors

Άρθρα Δημοσιευμένα στην Review of Clinical Pharmacology and Pharmacokinetics-Διεθνής Έκδοση
Articles Published in Review of Clinical Pharmacology and Pharmacokinetics-International Edition

Συντακτικη Επιτροπή-Editorial Board

Bookmark the permalink.

Comments are closed.